| Literature DB >> 25064343 |
Ming-Fang He1, Xiao-Ping Gao1, Shu-Chun Li1, Zhi-Heng He2, Ning Chen1, Yu-Bin Wang1, Jin-Xiong She3.
Abstract
Angiogenesis plays an essential role in many physiological and pathological processes. Auranofin (Ridaura®), an important gold(I) complex, is used to treat rheumatoid arthritis. However, the effect of auranofin on blood vessel formation is still unclear. In this study, we investigated the anti-angiogenic activity of auranofin on human umbilical vein endothelial cells (HUVEC) in vitro and zebrafish in vivo. Our results showed that auranofin could inhibit the proliferation, migration and tube formation of HUVECs and disrupted the formation of intersegmental vessels and the subintestinal vessels of zebrafish embryos. Auranofin inhibited the phosphorylation of vascular endothelial growth factor 2 (p-VEGFR2) on HUVECs and suppressed the vascular endothelial growth factor (VEGF) signaling pathway (vegfa, flt-1, kdr) but not thioredoxin reductase (TrxR) on zebrafish. Our study suggested that auranofin might serve as a potential anti-angiogenic compound candidate.Entities:
Keywords: Angiogenesis inhibitor; Auranofin; Auranofin (PubChem CID: 24199313); HUVEC; Zebrafish
Mesh:
Substances:
Year: 2014 PMID: 25064343 DOI: 10.1016/j.ejphar.2014.07.034
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432